TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05615298

Intervention type: RADIATION
Intervention: Mammography
Description: FFDM (Full-Field Digital mammography)

Intervention type: RADIATION
Intervention: Mammography
Description: FFDM (Full-Field Digital mammography)
Study: NCT02592330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft
Description: Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cultivation of Limbal epithelial cells into a graft
Description: A graft is manufactured for transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CALEC Transplant
Description: Limbal epithelial cells are obtained from the healthy fellow eye and cultivated in a lab for later transplantation into the diseased eye.
Study: NCT04117932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab (90 mg subcutaneously at weeks 0, 4, 16), in association with topical superpotent corticosteroid (10-30 g per day during the first 4 weeks, then every other day during 4 weeks).
Study: NCT03912857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Experimental: test group Drug:Camrelizumab(SHR-1210) 200mg, once every 2 weeks, each 4 weeks is 1cycle.~Apatinib :250 mg or 375 mg, qd
Study: NCT01194960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TroVax
Description: Trovax on Days 1,10, 22 and then Weeks 7, 10, 13, 19, 25, 31 and 37
Study: NCT01380327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cockroach Sublingual Immunotherapy (SLIT) - Low Dose
Description: Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume \[w/v\]) was achieved.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cockroach Sublingual Immunotherapy (SLIT) - High Dose
Description: Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume \[w/v\] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
Study: NCT00476476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Orally every day for about 4-6 weeks
Study: NCT02271126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEG monitoring
Description: anticoagulation monitoring during ECMO will be according to TEG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: APTT monitoring
Description: anticoagulation monitoring during ECMO will be according to aPTT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Anticoagulation provided to patients in ECMO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Anticoagulation provided to patients in ECMO
Study: NCT03056755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg of alpelisib film-coated tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg of alpelisib film-coated tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: 300 mg of alpelisib film-coated tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg of fulvestrant via intramuscular injection administered on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter. Cycle=28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg of letrozole film-coated tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg of goserelin via injectable subcutaneous implant administered every 28 days. Only for men in Cohort B and premenopausal women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg of leuprolide via injectable intramuscular depot administered every 28 days. Only for men in cohort B and premenopausal women.
Study: NCT03713593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib
Description: Administered orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenvatinib
Description: Administered orally once a day

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Administered as an IV infusion on Day 1 Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline placebo
Description: Administered as an IV infusion on Day 1 Q3W
Study: NCT03923959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injectable Solution
Description: 100 cc normal saline mixed with 1g of tranexamic acid in solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 cc normal saline
Study: NCT02964936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: roxadustat
Description: Oral administration
Study: NCT04515576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3493269
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT04405934

Intervention type: OTHER
Group type: OTHER
Intervention: Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures
Description: Rapid or standard (time to return to sites) receipt of virus (Covid-19) genomic sequencing reports
Study: NCT02706002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fluoroscopy
Description: in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip prosthesis
Description: all patients in the study will undergo hip prosthesis

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: hip prosthesis
Description: all patients in the study will undergo hip prosthesis
Study: NCT00902824

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ADVAX
Description: Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10\^7 pfu TBC-M4 (IM)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TBC-M4
Description: Receive 5x10\^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.~Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM.
Study: NCT02168270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ascorbic acid
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03276910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: 6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: 6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride AGUETTANT 0.9%
Description: 6 injections at 1ml in subcutaneous use
Study: NCT02561988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Study: NCT02565485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's
Description: 1500 cc of IV Fluid (crystalloid) used for preload prior to epidural administration in the treatment arm. Control arm receives 500 cc.
Study: NCT03677778

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline injected via interscalene nerve catheter
Description: With the catheter covered, treatment group patients will receive a normal saline (NS) bolus regimen (30cc 0.9% NS) via their interscalene nerve block catheter.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: With the catheter covered, placebo group patients will go through the same steps as the treatment group, but no solution will be injected into the interscalene nerve block catheter.
Study: NCT02103647

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release capsule(lyrica 150mg * 2/day)
Description: Immediate release capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sustained release tablet
Description: sustained release tablet
Study: NCT01710852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS CRP Rx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00789802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: transdermal estradiol
Description: transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen
Description: naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral placebo
Description: oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
Study: NCT04158830

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin 81 mg Enteric Coated Tab - 1 tablet
Description: take one (1) 81 mg tablet each evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 81 mg Enteric Coated Tab - 2 tablets
Description: take two (2) 81 mg tablets each evening
Study: NCT00377026

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
Study: NCT02318485

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Limbal epithelial stem cell graft
Study: NCT03264989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizanlizumab
Description: Crizanlizumab was administered IV infusion over 30 minutes at the assigned dose on Week 1 Day 1, Week 3 Day 1, and then Day 1 of every 4-week cycle. Cycle = 28 days
Study: NCT01919008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral
Study: NCT04172038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be delivered using a guideline-concordant approach based off the Department of Defense -Veterans Affairs Low Back Pain Guidelines, focusing on risk-stratified care deliver (using the STarT Back tool as an adjunct).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 2 Health (M2H)
Description: Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Move 2 Health (M2H)
Description: Participants will receive education for self-management (video and written materials) to introduce the key domains of holistic health in the Move to Health (M2H) model and their relationship to chronic LBP. Next, the participant will complete a Personal Health Inventory. The Inventory will be reviewed by the health coach and patient in order to identify specific domains for priority based on patient preference:~1. Sleep~2. Physical Activity~3. Nutrition~4. Intrinsic Well-Being (Personal Development, Spiritual Well-Being, Emotional Well-Being)~5. Extrinsic Well-Being (Family/Social Relationships, Surroundings)~Care may range from guided self-management with the researcher to a specialist referral (e.g., sleep specialist, dietician, behavioral health provider, etc.).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MORE Mindfulness
Description: Throughout the intervention, three core areas are emphasized. Activities include exercises and at-home work for participants to reinforce these core areas.~1. Mindfulness~2. Cognitive reappraisal~3. Savoring of positive experiences
Study: NCT03785600

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning Bright Light Therapy
Description: Morning bright light: Sitting in front of a lightbox for 60 minutes every morning within 90 minutes of waking up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Negative Ion Generator
Description: Negative ion generator: Sitting in front of a modified negative ion generator for 60 min every morning within 90 minutes of waking up.
Study: NCT04026555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MEWS++ Monitoring
Description: Patient's electronic medical record data will undergo processing by a machine learning algorithm (MEWS++).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Predictor Score
Description: A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Predictor Score
Description: A score predicting the likelihood that the patient will experience a deterioration in their clinical condition within six hours will be generated. If the prediction score exceeds a predetermined threshold, an alert will be sent to the provider. The alerting protocol is tiered, with both a low and high threshold. If the score is above the low threshold, nursing will be notified. If the score is above the high threshold, RRT will be notified.
Study: NCT04219280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quillivant XR
Description: Long-lasting liquid solution of Quillivant XR.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid solution to mimic the color and taste of Quillivant XR.
Study: NCT02716246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX111
Description: Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX111
Description: Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX111
Description: Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UX111
Description: Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Immunomodulatory (IM) Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Immunomodulatory (IM) Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Immunomodulatory (IM) Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimized Prophylactic IM Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant IM Therapy
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant IM Therapy
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant IM Therapy
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant IM Therapy
Description: The Principal Investigator and/or caregiver, in consultation with the medical monitor, will determine whether to initiate adjuvant IM therapy. Not all participants may receive adjuvant IM therapy.
Study: NCT00782340

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: 100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
Study: NCT02669823

Intervention type: OTHER
Intervention: None, treatment as actual best practice

Intervention type: OTHER
Intervention: None, treatment as actual best practice
Study: NCT02904304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine+Phenylephrine+Ibuprofen
Description: 01 tablet, orally, every 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 01 tablet, orally, every 12 hours.
Study: NCT02775526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOT
Description: 70 patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT
Description: 70 patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Burch Colposuspension
Description: 70 patients